H.C. Wainwright initiated coverage of Kyverna Therapeutics with a Neutral rating and $8 price target. Kyverna is a clinical stage biotech company focused on the treatment of rheumatic and neurologic diseases using one-time DNA-modified cell therapies, the analyst tells investors in a research note. The firm awaits data demonstrating clinically meaningful, durable responses to become more positive on the opportunity ahead for Kyverna.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYTX:
- Oppenheimer doesn’t understand why Cartesian hit by emerging CAR-T short thesis
- Kyverna Therapeutics participates in a conference call with JPMorgan
- Kyverna Therapeutics’ KYV-101 receives U.S. FDA IND clearance
- Kyverna Therapeutics announces report describing the first use of KYV-101
- After Kyverna data, Oppenheimer says Cartesian ‘can exploit’ CAR-T’s ‘baggage’